HC Wainwright Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its target price reduced by HC Wainwright from $47.00 to $40.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently issued reports on the stock. Truist Financial decreased their price target on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating for the company. Wedbush downgraded shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. Finally, Scotiabank reduced their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research report on Thursday, January 16th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Keros Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Stock Performance

Shares of KROS stock opened at $11.08 on Thursday. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00. The company has a 50 day moving average price of $12.52 and a 200 day moving average price of $39.52. The stock has a market capitalization of $448.82 million, a P/E ratio of -2.13 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. On average, research analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after purchasing an additional 46,041 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock valued at $15,105,000 after purchasing an additional 32,492 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Keros Therapeutics in the 4th quarter valued at $388,000. Barclays PLC raised its position in Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Keros Therapeutics in the 3rd quarter valued at $603,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.